Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1634 1682
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17489677 | METHODS AND SYSTEMS TO IMPROVE THE SIGNAL TO NOISE RATIO OF DNA METHYLATION PARTITIONING ASSAYS | Non-Final OA | GUARDANT HEALTH, INC. |
| 18174491 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | Non-Final OA | The Regents of The University of California |
| 18261091 | LAYERED ANALYSIS OF METHYLATED BIOMARKERS FOR USE IN CANCER DIAGNOSIS AND PROGNOSIS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 16848989 | NONINVASIVE DIAGNOSTICS BY SEQUENCING 5-HYDROXYMETHYLATED CELL-FREE DNA | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18023598 | PREDICTION OF A RESPONSE OF A PROSTATE CANCER SUBJECT TO THERAPY OR PERSONALIZATION OF THERAPY OF A PROSTATE CANCER SUBJECT | Non-Final OA | KONINKLIJKE PHILIPS N.V. |
| 18381126 | Markers of Triple-Negative Breast Cancer and Uses Thereof | Final Rejection | Vanderbilt University |
| 17984444 | SURFACE-ENHANCED RAMAN SCATTERING (SERS) BIOSENSOR FOR DIAGNOSING PROSTATE CANCER WITH HIGH SENSITIVITY | Non-Final OA | Korea University Research and Business Foundation |
| 18009013 | METHODS OF DETECTING METHYLATED CpG | Final Rejection | Ramot at Tel-Aviv University Ltd. |
| 17634217 | METHOD FOR ALTERING THERAPY OF ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS BASED ON ANALYSIS OF ctDNA | Final Rejection | Dana-Farber Cancer Institute, Inc. |
| 19180820 | CUSTOMIZED ASSAYS FOR PERSONALIZED CANCER MONITORING | Non-Final OA | Personalis, Inc. |
| 18557747 | COMPOSITIONS AND METHODS FOR CHIMERIC AMPLICON FORMATION | Non-Final OA | William Marsh Rice University |
| 18463282 | USE OF SDHA AS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN UVEAL MELANOMA | Final Rejection | Board of Regents, The University of Texas System |
| 18977532 | METHOD FOR EARLY DETECTION, PREDICTION OF TREATMENT RESPONSE AND PROGNOSIS OF LUNG CANCER | Non-Final OA | EG BIOMED CO., LTD. |
| 18261874 | METHODS FOR DETECTING utDNA | Non-Final OA | Washington University |
| 18894793 | METHOD FOR IDENTIFYING TARGETS FOR PRECISION CANCER THERAPY | Non-Final OA | Tampere University Foundation Sr |
| 18540517 | BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17887727 | COMPOSITIONS AND METHODS FOR ONCOLOGY PRECISION ASSAYS | Final Rejection | Life Technologies Corporation |
| 17250610 | REAGENTS, MIXTURES, KITS AND METHODS FOR AMPLIFICATION OF NUCLEIC ACIDS | Final Rejection | Life Technologies Corporation |
| 17690817 | B CELL-ENRICHED TUMOR MICROENVIRONMENTS | Final Rejection | Cornell University |
| 18013368 | IDENTIFICATION OF ESTROGEN RECEPTOR POSITIVE (ER+) BREAST CANCERS THAT WILL NOT DEVELOP TAMOXIFEN RESISTANCE | Non-Final OA | Rutgers, The State University of New Jersey |
| 16309271 | COMPOSITIONS AND METHODS FOR DETECTION OF NUCLEIC ACID MUTATIONS | Final Rejection | Natera, Inc. |
| 18269171 | SELECTIVE LYSIS OF HUMAN BLOOD CELLS | Non-Final OA | Roche Molecular Systems, Inc. |
| 17914050 | BIOMARKER PANELS FOR STRATIFICATION OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN CANCER | Final Rejection | CEDARS-SINAI MEDICAL CENTER |
| 17596758 | DETECTION OF RELB ACTIVATION FOR PREDICTING A PROGNOSTIC IN B-CELL LYMPHOMA | Final Rejection | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE |
| 18015989 | Methods for Classifying Cancer | Non-Final OA | Kingston Health Sciences Centre |
| 18339106 | USE OF CIRCULATING CELL-FREE RNA FOR DIAGNOSIS AND/OR MONITORING CANCER | Non-Final OA | Liquid Genomics, Inc. |
| 18267732 | Method for Evaluating Adapter Ligation Efficiency in Sequencing of DNA Sample | Non-Final OA | GENODIVE PHARMA INC. |
| 17795848 | COMPOSITION USING CPG METHYLATION CHANGES IN SPECIFIC GENES TO DIAGNOSE BLADDER CANCER, AND USE THEREOF | Final Rejection | GENCURIX INC. |
| 18013178 | METHOD FOR DETECTING COLORECTAL CANCER | Non-Final OA | ACADEMISCH ZIEKENHUIS MAASTRICHT |
| 18027425 | METHOD OF PREDICTING CANCER RECURRENCE USING PATIENT-SPECIFIC PANEL | Non-Final OA | IMB Dx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy